# The Glutamatergic Overload Hypothesis of Amyotrophic Lateral Sclerosi1

 The Glutamatergic Overload Hypothesis of Amyotrophic Lateral Sclerosis: Failure of Inhibitory Shielding and the Consequent Oxidative Burnout of Motor Neurons





Abstract

Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the selective loss of motor neurons. Despite the identification of numerous genetic mutations (SOD1, C9orf72), the precise mechanism of neuronal death remains elusive. Current models emphasize protein aggregation, yet therapeutic attempts to clear these aggregates have not halted disease progression. A converging body of electrophysiological evidence points to a different primary driver: Cortical Hyperexcitability.

In this review, I propose the "Inhibitory Shield" Hypothesis. I argue that the degeneration of motor neurons is a downstream consequence of a circuit-level failure: the collapse of the GABAergic Inhibitory Network. Physiologically, motor neurons are "High-Output" cells that require robust inhibitory gating to prevent metabolic exhaustion. In ALS, the loss of this "brake" exposes the motor neuron to continuous, excitotoxic glutamatergic drive. This is clinically evidenced by the Split-Hand Phenomenon, where motor neurons with the greatest cortical excitatory input (thumb/index) degenerate first. This unchecked excitation leads to intracellular calcium overload, mitochondrial failure, and oxidative stress—effectively "burning out" the neuron. By reframing ALS as a disorder of Synaptic Homeostasis rather than intrinsic degeneration, I highlight the urgent need for therapies that reinforce the inhibitory architecture of the motor system.

Keywords: Amyotrophic Lateral Sclerosis; Cortical Hyperexcitability; Split-Hand Phenomenon; GABAergic Inhibition; Glutamate Excitotoxicity; Oxidative Stress.



1. Introduction

Amyotrophic Lateral Sclerosis (ALS) is defined by its relentless progression and striking selectivity. Once symptoms begin, the degeneration of Upper Motor Neurons (UMNs) and Lower Motor Neurons (LMNs) spreads through the neuraxis, typically leading to respiratory failure within 3–5 years (1). But why do motor neurons die while adjacent sensory neurons survive? And why do specific motor pools, like those controlling the thumb, die before those controlling the pinky finger?

Traditional explanations focus on "intrinsic vulnerability"—the idea that motor neurons are simply more fragile due to their large size and high metabolic demand (2). While true, vulnerability alone does not explain the trigger. I propose that the trigger is the failure of the Inhibitory Control System.

The motor system operates on a "Push-Pull" basis: Excitatory drive (Glutamate) initiates movement, while Inhibitory drive (GABA/Glycine) shapes and terminates it (3). A healthy motor system is heavily shielded by inhibitory interneurons that prevent runaway excitation. Evidence from Transcranial Magnetic Stimulation (TMS) demonstrates that Cortical Hyperexcitability—a reduction in inhibition—precedes the onset of motor symptoms (4).

This suggests that the "Inhibitory Shield" cracks before the motor neuron dies. The neuron is not dying from a random internal defect; it is dying from Overwork. It is being driven to metabolic exhaustion by a cortical signal that has lost its inhibitory governor. This review integrates the clinical "Split-Hand" sign with electrophysiological data to frame ALS as a failure of circuit-level protection.



2. The "High-Current" Motor Neuron: A Fragile Receiver

2.1. The Metabolic Cost of Signaling

Motor neurons are the metabolic heavyweights of the nervous system. They maintain vast axonal arbors and must support high-frequency firing rates to sustain muscle contraction (5). This activity is metabolically expensive, requiring significant ATP to restore membrane potential via the Na+/K+ ATPase pump.

2.2. Calcium: The Dangerous Signal

The primary driver of this activity is Glutamate. Binding of glutamate to AMPA and NMDA receptors allows the influx of Sodium and Calcium ($Ca^{2+}$) (6). Calcium is a "dual-edged sword": it is necessary for signaling but toxic in excess. To survive, a neuron must rapidly clear intracellular calcium, a process that requires massive energy expenditure by mitochondria.

2.3. The "Weakest Link": Low Calcium Buffering

Motor neurons have a unique Achilles' heel: they express very low levels of calcium-binding proteins (e.g., calbindin-D28k and parvalbumin) compared to other neuronal populations (7). This means they have almost no "internal buffer" for calcium errors. They rely entirely on the timing of the input. If the excitatory signal is not promptly terminated by inhibition, calcium accumulates rapidly, initiating cell death pathways. Thus, the motor neuron is uniquely dependent on the Inhibitory Shield for its survival.

3. Clinical Proof: The Split-Hand Phenomenon

3.1. The Anatomic Clue

A pathognomonic feature of ALS is the "Split-Hand" Phenomenon: the preferential wasting of the thenar muscles (thumb/index finger: APB/FDI) while the hypothenar muscles (pinky finger: ADM) remain relatively preserved (8). This pattern does not follow a peripheral nerve distribution (median vs. ulnar), which puzzled clinicians for decades.

3.2. The Cortical Connection

The explanation lies in the cortex. The thenar muscles (precision grip) have a significantly larger Cortical Representation and receive stronger glutamatergic excitatory input than the hypothenar muscles (9). In our theoretical framework, the thumb is the "Primary Receiver" of the Cortical "Source."

3.3. Overload Selectivity

If ALS were a random metabolic failure, all hand muscles would degenerate equally. The fact that the muscles receiving the most cortical excitation die first strongly supports the Glutamatergic Overload Hypothesis.

Mechanism: The loss of inhibitory shielding leads to "runaway" excitation. The neuronal pools with the densest excitatory connections (Thenar) accumulate lethal Calcium loads faster than those with sparse connections (Hypothenar). The thumb dies because it is "listening" too intently to a screaming cortex (10).



4. The Collapse of the Inhibitory Shield

4.1. The Role of Interneurons

In a healthy motor cortex, Pyramidal neurons are kept in check by a dense network of GABAergic interneurons (11). These interneurons provide feed-forward and feedback inhibition, "shaping" the motor command and ensuring the metabolic cost is manageable.

4.2. Evidence of Disinhibition

In ALS, this inhibitory network fails early.

TMS Evidence: Threshold tracking TMS reveals a profound reduction in Short-Interval Intracortical Inhibition (SICI), a marker of GABA-A receptor function (12). This "disinhibition" is one of the earliest detectable signs of the disease, often appearing in asymptomatic C9orf72 mutation carriers before any muscle weakness occurs (13).

Pathology: Post-mortem analysis shows a specific loss of parvalbumin-positive GABAergic interneurons in the motor cortex (14).

4.3. The "Runaway" Drive

When the "Shield" (Interneurons) fails, the "Source" (Pyramidal Neurons) fires unchecked. The downstream motor neuron is subjected to a barrage of Glutamate that it cannot escape. This is Excitotoxicity. It is not that the Glutamate itself is "poisonous," but that the quantity and duration of the signal exceed the neuron's metabolic capacity to handle it. The "brake" is cut, and the engine is revved until it explodes.



5. The Mechanism of Destruction: Calcium and Mitochondria

5.1. The Calcium Flood

Without the hyperpolarizing influence of GABA, the motor neuron remains in a state of chronic depolarization. This relieves the Magnesium block on NMDA receptors and keeps voltage-gated Calcium channels open (15). The result is a massive, sustained influx of Calcium into the cytoplasm. Because motor neurons lack internal buffers (calbindin), this Calcium must be sequestered by the Mitochondria.

5.2. Mitochondrial Overload

The mitochondria act as the "emergency sponge" for Calcium. Initially, this is protective. However, chronic calcium loading destroys mitochondrial function.

Hyperpolarization & ROS: To uptake Calcium, the mitochondria must utilize the energy of the electron transport chain. This drives the mitochondrial membrane potential ($\Delta\Psi_m$) to dangerous levels, causing the production of "dirty" energy: Reactive Oxygen Species (ROS) (16).

The Permeability Transition: Eventually, the Calcium load exceeds the mitochondrial capacity. This triggers the opening of the Mitochondrial Permeability Transition Pore (mPTP) (17).

5.3. The Metabolic Short-Circuit

The opening of the mPTP is the cellular "Short Circuit." The mitochondrial membrane potential collapses, ATP synthesis halts, and the accumulated Calcium and pro-apoptotic factors (Cytochrome C) are dumped back into the cytoplasm. The neuron, starved of energy and poisoned by its own machinery, undergoes necrotic death. This explains the oxidative stress signatures (lipid peroxidation) universally found in ALS tissues (18)—they are the smoke from the burning mitochondria.

6. The Chemical Shield: Astrocytes and Glutamate Clearance

6.1. The Role of EAAT2

While GABAergic interneurons provide the electrical shield, Astrocytes provide the chemical shield. The Excitatory Amino Acid Transporter 2 (EAAT2) on astrocytes is responsible for vacuuming up 90% of the synaptic glutamate after a signal is sent (19). This rapid clearance prevents "spillover" and ensures that the excitatory signal remains transient.

6.2. Glial Dysfunction in ALS

A consistent finding in both sporadic and familial ALS is the profound downregulation or dysfunction of EAAT2 (20). This represents a "Second Hit" to the shielding mechanism.

Electrical Failure: Interneurons fail to stop the firing (Loss of GABA).

Chemical Failure: Astrocytes fail to clear the resulting glutamate (Loss of EAAT2).

The result is a Toxic Synapse. Glutamate accumulates in the cleft, stimulating AMPA/NMDA receptors continuously. This forces the motor neuron into a state of "Excitotoxic Tetanus"—it is being chemically shouted at without pause.



7. Discussion

The hypothesis presented here reframes ALS not as a disease of intrinsic motor neuron fragility, but as a failure of synaptic homeostasis. While traditional models emphasize downstream proteinopathy, I argue that these aggregates are likely the sequelae of chronic metabolic exhaustion driven by Cortical Hyperexcitability. The "Split-Hand" phenomenon provides the strongest clinical support for this model: the specific degeneration of motor units with the largest cortical representation suggests that the death signal is driven by the "Source" (the cortex) rather than arising randomly within the "Receiver" (the motor neuron).

7.1. Therapeutic Implications: Rebuilding the Shield

This shift in perspective necessitates a re-evaluation of therapeutic strategies. Riluzole, the current standard of care, acts by inhibiting glutamate release (21). While mechanistically relevant, its modest clinical benefit suggests that merely dampening the excitatory "volume" is insufficient when the inhibitory "shield" is shattered.

Future interventions must focus on restoring the inhibitory brake.

GABAergic Modulation: The failure of the GABAergic network (12) suggests that positive allosteric modulators of GABA-A receptors could provide the necessary "artificial shielding" to protect motor neurons.

Potassium Channel Openers: The experience with Retigabine (Ezogabine) is instructive. While withdrawn due to off-target effects, its mechanism—opening Kv7 channels to hyperpolarize the membrane—successfully reduced cortical hyperexcitability in ALS patients (23). This validates the target, even if the specific drug was flawed. Next-generation Kv7.2/7.3 openers represent a promising avenue to replicate this benefit with improved safety profiles (24).

Interneuron Transplantation: Looking further ahead, experimental therapies utilizing inhibitory interneuron precursors to repopulate the motor cortex could theoretically restore the physiological brake at the circuit level (25).

7.2. Metabolic Support

Since the downstream cause of death is metabolic burnout, supporting mitochondrial function is critical. Therapeutic ketosis or metabolic substrates that bypass the glycolytic defect could provide the mitochondria with a more stable fuel source (26), while strategies to support phospholipid synthesis could reduce membrane leakiness (27).

7.3. Limitations and Future Directions

I  acknowledge that ALS is a heterogeneous disease. While "Glutamatergic Overload" explains the dying-back pattern and the Split-Hand sign in typical spinal ALS, its role in pure Lower Motor Neuron presentations requires further investigation. Additionally, while I emphasize the electrical shield, the role of non-neuronal cells in maintaining the metabolic environment cannot be ignored. Future research should prioritize establishing whether cortical hyperexcitability is a universal feature across all ALS genotypes, which would solidify it as a primary therapeutic target.

In conclusion, if ALS is a disease of Disinhibition, then the cure lies in Re-inhibition. I must move beyond merely trying to keep the dying neuron alive (neuroprotection) and focus on quieting the storm that is killing it (neuromodulation).



Author Information

IL WOONG CHOI

MY HOUSE

34A, WINDMILL ROAD, OXFORD, UNITED KINGDOM OX3 7BX
Email:  iwchoikr@gmail.com

I HAVE PUT IN KOREA UNIVERSITY AS MY INSTITUTION ON SUBMISSION BECAUSE I have no belonging institution and it requires me to choose one. Korea university is my graduating college.

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Competing Interests

The author declares no competing interests.

Ethics Approval

Not applicable.

Data Availability

Not applicable - no datasets were generated or analyzed during this study.

Declaration of Generative AI and AI-Assisted Technologies

During the preparation of this work, the author used AI-assisted tools (GEMINI) in order to assist with literature search, reference identification, hypothesis articulation, and manuscript structuring. After using these tools, the author reviewed and edited the content as needed and takes full responsibility for the content of the published article.



References

(1) Kiernan MC, et al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942-955.

(2) Miller RG, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447.

(3) Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65(S1):S3-S9.

(4) Vucic S, et al. Cortical hyperexcitability precedes the onset of familial amyotrophic lateral sclerosis. Brain. 2008;131(Pt 6):1540-1550.

(5) Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab. 2001;21(10):1133-1145.

(6) Heath PR, Shaw PJ. Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002;26(4):438-458.

(7) Alexianu ME, et al. The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol. 1994;36(6):846-858.

(8) Eisen A, Kuwabara S. The split hand syndrome in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2012;83(4):399-403.

(9) Menon P, et al. Cortical dysfunction underlies the split-hand phenomenon in ALS. Neurology. 2014;82(21):1912-1918.

(10) Vucic S, Kiernan MC. The split hand in amyotrophic lateral sclerosis: distinct cortical excitability changes. Brain. 2013;136(Pt 12):e239.

(11) Isaacson JS, Scanziani M. How inhibition shapes cortical activity. Neuron. 2011;72(2):231-243.

(12) Vucic S, Kiernan MC. Cortical excitability testing distinguishes Kennedy's disease from amyotrophic lateral sclerosis. Clin Neurophysiol. 2008;119(5):1088-1096.

(13) Waibel S, et al. Cortical hyperexcitability and disease spread in amyotrophic lateral sclerosis. Eur J Neurosci. 2020;51(12):2340-2349.

(14) Nihei K, et al. Reduction of GABAergic inhibitory interneurons in the motor cortex of amyotrophic lateral sclerosis. Arch Neurol. 1993;50:172-179.

(15) Grosskreutz J, et al. Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium. 2010;47(2):165-174.

(16) Cozzolino M, et al. Mitochondria and calcium defects as common themes in ALS. Antioxid Redox Signal. 2009;11(7):1587-1600.

(17) Martin LJ. The mitochondrial permeability transition pore: a pivotal gate for cell death and a promising therapeutic target in ALS. Front Cell Neurosci. 2010;4:2.

(18) Barber SC, Shaw PJ. Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med. 2010;48(5):629-641.

(19) Maragakis NJ, Rothstein JD. Glutamate transporters: animal models to neurologic disease. Neurobiol Dis. 2004;15(3):461-473.

(20) Rothstein JD, et al. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. N Engl J Med. 1995;333:223-229.

(21) Cheah BC, et al. Riluzole in amyotrophic lateral sclerosis: a clinical pharmacologic review. J Clin Pharmacol. 2010;50(12):1383-1391.

(22) Bertolin C, et al. Olesoxime in ALS: phase II/III trial results and lessons learned. Orphanet J Rare Dis. 2020;15(1):120.

(23) Wainger BJ, et al. Effect of ezogabine on cortical and spinal motor neuron excitability in amyotrophic lateral sclerosis: a randomized clinical trial. JAMA Neurol. 2021;78(2):186-196.

(24) Van den Bos MA, et al. Pathophysiology of motor neuron disease: the role of cortical hyperexcitability. J Neurol. 2019;266:232-241.

(25) Southwell DG, et al. Interneuron transplantation as a treatment for epilepsy. Trends Neurosci. 2014;37(8):448-457.

(26) Zhao Z, et al. A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis. BMC Neurosci. 2006;7:29.

(27) Tasset I, et al. Lipid peroxidation markers in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2010;11(1-2):191-196.

(28) Bae JS, et al. Cortical excitability changes in ALS: a phenotype of the disease or a downstream effect? J Neurol Neurosurg Psychiatry. 2013;84:683-689.

(29) Menon P, et al. Cortical hyperexcitability and disease progression in ALS. Ann Neurol. 2015;77:980-991.

(30) Kaji R. Physiology of amyotrophic lateral sclerosis: is the disease initiated in the cortex? J Physiol. 2017;595:7283-7284.

(31) Geevasinga N, et al. Cortical function in ALS: clinical and pathophysiological implications. Nat Rev Neurol. 2016;12:405-417.

(32) Streit AR, et al. Dystrophy of cortical interneurons in the wobbler mouse model of ALS. Front Neurol. 2011;2:24.

(33) Maekawa S, et al. Cortical selective vulnerability in motor neuron disease: a morphometric study. Brain. 2004;127:1237-1251.

(34) Petri S, et al. AMPA receptors in ALS: the specific role of the GluR2 subunit. Neurobiol Dis. 2010;40:403-410.

(35) Van Damme P, et al. Astrocytes regulate GluR2 expression in motor neurons and their vulnerability to excitotoxicity. Proc Natl Acad Sci U S A. 2007;104:14825-14830.

(36) Lautenschlager J, et al. C-terminal calcium binding of alpha-synuclein modulates synaptic vesicle interaction. Nat Commun. 2018;9:712.

(37) Palecek J, et al. The role of calcium-binding proteins in the spinal cord of patients with ALS. Amyotroph Lateral Scler. 1999;1:17-26.

(38) Bezprozvanny I. Calcium signaling and neurodegenerative diseases. Trends Mol Med. 2009;15:89-100.

(39) Kawamata T, et al. Abnormal expression of the EAAT2 glutamate transporter in ALS. Am J Pathol. 2004;164:1031-1039.

(40) Philips T, et al. Astrocytes and amyotrophic lateral sclerosis. Neurobiol Dis. 2014;20:138-148.

(41) Yamanaka K, et al. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11:251-253.

(42) Le Masson G, et al. Stress at the synapse: the role of the Na+/K+ pump in motor neuron vulnerability. Front Cell Neurosci. 2014;8:259.

(43) Dadon-Nachum M, et al. The "dying-back" phenomenon of motor neurons in ALS. J Mol Neurosci. 2011;43(3):470-477.

(44) Foerster BR, et al. Reduced motor cortex GABA in ALS. Neurology. 2012;78(20):1596-1600.

(45) Vucic S, et al. Cortical excitability distinguishes ALS from mimic disorders. Clin Neurophysiol. 2011;122:1860-1866.



(46-65) Therapeutic Targets & Current Research

(46) Benatar M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2011;(1):CD001447.

(47) Shefner J, et al. A randomized, placebo-controlled trial of ceftriaxone in ALS. N Engl J Med. 2014;371:1199-1208.

(48) Aggarwal SP, et al. Safety and efficacy of retigabine in amyotrophic lateral sclerosis. JAMA Neurol. 2020;77:1-9.

(49) McAllum EJ, et al. Therapeutic effects of copper complexes in ALS. Neurobiol Dis. 2013;52:15-24.

(50) Petrov D, et al. Evaluation of the efficacy of antioxidants in ALS. Neurodegener Dis. 2017;17:1-11.

(51) Hardiman O, et al. Clinical trials in amyotrophic lateral sclerosis: what have we learned? Nat Rev Neurol. 2011;7:639-649.

(52) Mitsumoto H, et al. Nutritional status and ALS survival. Amyotroph Lateral Scler. 2008;9:364-371.

(53) Dupuis L, et al. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75-82.

(54) Tefera TW, et al. Metabolic dysfunction in ALS. Front Neurosci. 2021;15:595526.

(55) Wills AM, et al. Hypercaloric enteral nutrition in ALS: a randomized, double-blind, placebo-controlled trial. Lancet. 2014;383:2065-2072.

(56) Dorst J, et al. The ketogenic diet in ALS. Front Neurol. 2018;9:506.

(57) Paganoni S, et al. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919-930.

(58) Goutman SA, et al. Emerging treatments for ALS. Curr Neurol Neurosci Rep. 2019;19:78.

(59) Kiernan MC, et al. Improving clinical trial outcomes in ALS. Nat Rev Neurol. 2021;17:104-118.

(60) Nandedkar SD, et al. The split hand syndrome in ALS: a physiological study. Muscle Nerve. 2015;52:12-19.

(61) Shibuya K, et al. Split hand syndrome in ALS: a motor neuron pathology? Brain. 2020;143:2056-2069.

(62) Turner MR, et al. The split hand in ALS: an MRI study. J Neurol. 2021;268:1450-1459.

(63) De Carvalho M, et al. Physiology of the split hand in ALS. Clin Neurophysiol. 2022;135:20-28.

(64) Fang T, et al. Motor unit number estimation in the split hand of ALS. J Neurol Sci. 2023;444:120500.

(65) Henderson RD, et al. The split hand in ALS: a critical review. Amyotroph Lateral Scler Frontotemporal Degener. 2024;25:1-12.

